The global monkeypox vaccine market size reached US$ 86.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032. More Info:- https://www.imarcgroup.com/monkeypox-vaccine-market

1. Global Monkeypox
Vaccine Market
Research and Forecast
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved

2. About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on management
strategy and market research worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their most critical challenges, and
transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods
are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting
results.

3. Report Highlight
and Description
According to the latest report by IMARC Group, titled "Monkeypox Vaccine
Market: Global Industry Trends, Share, Size, Growth, Opportunity and
Forecast 2024-2032," the global monkeypox vaccine market size reached US$
86.6 Million in 2023.
Factors Affecting the Growth of the Monkeypox Vaccine Industry:
Global Health Initiatives and Funding Increases:
The rise in international focus on infectious diseases is driving the demand for
vaccines against emerging threats like monkeypox. Governments, global health
bodies, and private entities are increasingly investing in vaccine development
and distribution frameworks to prevent widespread outbreaks.
This rise in funding not only facilitates the accelerated development and
approval of new vaccines but also enhances the manufacturing capabilities of
pharmaceutical companies. As a result, the capacity to produce vaccines at
scale and the ability to rapidly respond to emerging health crises are markedly
improving.

4. Report Highlight
and Description
Rising Incidence of Monkeypox Cases:
The noticeable increase in monkeypox cases across multiple regions globally is
supporting the growth of the market. This uptick is linked to several factors,
including greater human interaction with animal vectors and international
travel, which facilitates the cross-border transmission of the virus.
The growing awareness among public health authorities and surveillance of
monkeypox are leading to improved diagnosis rates, subsequently increasing
the perceived need for vaccination. The urgent demand for effective preventive
measures against a potential outbreak encourages healthcare systems and
governments to procure and stockpile adequate vaccine supplies.
Advancements in Vaccine Technology:
Recent technological advancements in vaccine research and development
(R&D) are bolstering the market growth. Innovations, such as messenger
ribonucleic acid (mRNA) vaccine technology, are being adapted for other
infectious diseases, including monkeypox.

5. Report Highlight
and Description
These technologies allow for quicker development and potentially more
effective vaccines, increasing their adoption rate. Moreover, the ability to
adjust existing platforms to target new pathogens reduces the time and cost
associated with vaccine development, making the process more efficient and
scalable. This factor not only enhances the production capacity of vaccine
manufacturers but also improves the global readiness to combat emerging
infectious diseases.
Request for a PDF sample of this report:
https://www.imarcgroup.com/monkeypox -vaccine-market/requestsample

6. Report Description
Global Monkeypox Vaccine Market Trends:
Increased public awareness about monkeypox and its transmission dynamics plays a significant role in driving
vaccine demand. As awareness grows, so does the willingness of the public to receive vaccinations, influenced by
targeted health communication strategies and public health campaigns. Furthermore, governments implementing
robust health policies that include vaccination programs as part of their disease prevention and control plans also
spur market growth.
These policies often mandate vaccine procurement and administration, supported by public health advisories and
educational campaigns that effectively increase community engagement and compliance. Thus, informed public
behavior combined with proactive governmental strategies enhances the overall demand for monkeypox vaccines.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/monkeypox-vaccine-market

7. Report
Segmentation
Breakup by Type:
• Replication-competent
• Replication-deficient
Breakup by Route of Administration:
• Subcutaneous
• Percutaneous
Breakup by Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

8. Report
Segmentation
Breakup by End User:
• Hospitals
• Clinics
• Others
Breakup by Region:
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

9. Key Questions
Answered in
the Report
How big is the global monkeypox vaccine market?
What is the expected growth rate of the global monkeypox
vaccine market during 2024-2032?
What are the key factors driving the global monkeypox
vaccine market?
What has been the impact of COVID-19 on the global
monkeypox vaccine market?
What is the breakup of the global monkeypox vaccine market
based on the route of administration?
What is the breakup of the global monkeypox vaccine market
based on the distribution channel?
What is the breakup of the global monkeypox vaccine market
based on end user?
What are the key regions in the global monkeypox vaccine
market?

10. Table of
Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Monkeypox Vaccine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Replication-competent
6.1.1 Market Trends
6.1.2 Mark et Forecast
6.2 Replication-deficient
6.2.1 Mark et Trends
6.2.2 Mark et Forecast
7 Market Breakup by Route of Administration
7.1 Subcutaneous
7.1.1 Mark et Trends
7.1.2 Mark et Forecast

11. Table of
Contents
7.2 Percutaneous
7.2.1 Mark et Trends
7.2.2 Mark et Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.1.1 Mark et Trends
8.1.2 Mark et Forecast
8.2 Retail Pharmacy
8.2.1 Mark et Trends
8.2.2 Mark et Forecast
8.3 Online Pharmacy
8.3.1 Mark et Trends
8.3.2 Mark et Forecast
8.4 Others
8.4.1 Mark et Trends
8.4.2 Mark et Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Mark et Forecast
9.2 Clinics
9.2.1 Mark et Trends
9.2.2 Mark et Forecast
9.3 Others
9.3.1 Mark et Trends
9.3.2 Mark et Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Mark et Trends
10.1.1.2 Mark et Forecast
For more information, visit :
https://www.imarcgroup.com/monkeypox -vaccine-market/toc

12. Partial List of Clients

13. Partial List of Clients

14. Disclaimer
© 2024 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the
name of International Market Analysis Research and Consulting (IMARC). No part of this
publication may be reproduced, repackaged, redistributed or resold in whole or in any part.
The publication may also not be used in any form or by and means graphic electronic or
mechanical, including photocopying, recording, taping or by information storage or retrieval,
or by any other form, without the express consent of International Market Analysis Research
and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and
opinion have been based on information and sources believed to be accurate and reliable at
the time of publishing. International Market Analysis Research and Consulting makes no
representation of warranty of any kind as to the accuracy or completeness of any Information
provided. IMARC accepts no liability whatsoever for any loss or damage resulting from
opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of
International Market Analysis Research and Consulting. All other trademarks used in this
publication are registered trademarks of their respective companies.

15. Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
sales@imarcgroup.com
Stay With Us: